Kymera Therapeutics (KYMR) stock drops 6.6% to start 2026 as insider sale filing stays in focus
Kymera Therapeutics shares fell 6.6% to $72.76 Friday after a filing showed CEO Nello Mainolfi exercised and sold 30,000 shares on Dec. 31. The stock underperformed biotech benchmarks as investors awaited U.S. jobs data and updates on Kymera’s 2026 clinical-trial plans.